In Vitro Efficacy Testing Services for Schistosomiasis

We provide robust and sensitive in vitro screening and characterization platforms for accelerating the discovery and screening of potential therapies for schistosomiasis. Our services enable the evaluation of compound efficacy and mechanism of action against schistosome-specific enzymes and molecular targets. Key targets for schistosomiasis research include proteases, histone-modifying enzymes, and signaling pathways crucial for parasite survival and pathogenicity. We assess drug effects on processes such as enzymatic activity, epigenetic regulation, and cellular signaling associated with schistosome infection and pathology.

Our in vitro efficacy testing encompasses a range of biochemical and cell-based assays tailored to schistosomiasis research. We utilize substrate-based enzymatic assays and sensitive luminescent or fluorescent readouts to accurately measure compound activity and target engagement.

Cbz-Lys-(acetyl)-7-amino-4-methylcoumarin as substrate: Used to assess protease or epigenetic enzyme activity by detecting cleavage or modification events; provides quantitative measurement of enzyme inhibition.

Fluorescent assay: Employs fluorescent substrates or probes to monitor enzyme activity or cellular processes in real-time, enabling high-sensitivity detection of target modulation.

Histone H3 as substrate: Evaluates epigenetic enzyme activity by measuring post-translational modifications of histone proteins, important for understanding gene regulation in schistosomes.

Luciferine/luciferase assay: Utilizes bioluminescent signals to quantify enzyme reactions or cellular viability, offering a highly sensitive approach for detecting compound efficacy.

p53 peptide as substrate: Measures modification or cleavage of the p53 peptide, allowing investigation of pathways involved in cell cycle regulation and parasite survival.

We measure key pharmacological parameters such as IC-50 and MIC to quantify compound potency and efficacy. These parameters are essential for comparing the effectiveness of drug candidates and guiding further optimization.

IC-50: The concentration of a compound required to inhibit 50% of target enzyme activity or cellular function; a critical metric for assessing compound potency and selecting leads for further development.

MIC: Minimum inhibitory concentration, representing the lowest concentration of a compound that visibly inhibits parasite growth; vital for determining effective therapeutic doses and prioritizing candidates for in vivo studies.

Recommended In Vitro Efficacy Tests

Androgen Receptor

Androgen Receptor (AR) testing is crucial in schistosomiasis drug development, as AR signaling influences parasite survival and reproduction. Assessing candidate compounds using a luciferin/luciferase reporter assay enables precise measurement of AR activity modulation. Determining the IC-50 value for each compound quantifies its potency in inhibiting AR, guiding the selection of effective drug candidates targeting AR pathways in schistosomes.

Creb Binding Protein

The Creb Binding Protein (CBP) is vital for gene regulation in Schistosoma parasites. Testing CBP activity is crucial for identifying potential anti-schistosomiasis compounds. This service uses Histone H3 as a substrate to assess CBP-mediated acetylation. The main parameter measured is IC-50, indicating compound potency in inhibiting CBP activity, which supports targeted drug development against schistosomiasis.

Fatty Acid Amide Hydrolase

Fatty Acid Amide Hydrolase (FAAH) is crucial for parasite lipid signaling in schistosomiasis. Inhibiting FAAH may disrupt parasite survival, making it a valuable drug target. Our FAAH testing service uses a sensitive fluorescent assay to evaluate compound efficacy. The primary parameter measured is IC50, indicating the concentration required to inhibit FAAH activity by 50%, enabling rapid assessment of potential schistosomiasis therapeutics.

Histone Deacetylase 6

Histone Deacetylase 6 (HDAC6) plays a critical role in schistosomiasis by regulating parasite gene expression and viability. HDAC6 inhibition is a promising drug development target. Our testing service utilizes a fluorescent assay with Cbz-Lys-(acetyl)-7-amino-4-methylcoumarin as the substrate to assess compound efficacy against HDAC6. The key parameter measured is IC50, enabling accurate evaluation of inhibitor potency for schistosomiasis drug candidates.

Histone Deacetylase 8

The Histone Deacetylase 8 (HDAC8) testing service targets a crucial enzyme involved in Schistosoma parasite survival, making it a promising drug target for schistosomiasis. This assay uses a p53 peptide substrate and a fluorescent readout to evaluate inhibitor potency, with IC-50 values as the primary parameter. Accurate HDAC8 inhibition profiling accelerates the development of novel, effective antischistosomal compounds.

Prostaglandin-Endoperoxide Synthase 1

Prostaglandin-Endoperoxide Synthase 1 (PTGS1/COX-1) is implicated in schistosomiasis pathogenesis by mediating inflammatory responses. Testing PTGS1 is vital for identifying and evaluating new drug candidates targeting inflammation in schistosomiasis. Key methods include enzyme activity assays and inhibitor screening using parasite or host-derived proteins. Main parameters assessed are enzyme activity levels, inhibitor potency (IC50), and selectivity, providing critical data for drug development and efficacy.

Thioredoxin Reductase 1

Thioredoxin Reductase 1 (TrxR1) is a crucial enzyme in Schistosoma redox homeostasis, making it a valuable drug target for schistosomiasis. Our TrxR1 testing service utilizes a sensitive fluorescent assay to evaluate compound efficacy. The primary parameter measured is the Minimum Inhibitory Concentration (MIC), enabling rapid identification and optimization of potential antischistosomal agents targeting TrxR1.